Acorda Therapeutics Inc. ($ACOR) stock jumped up as the company announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes review (IPR) process. These patents were Nos. 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent) , set to expire in 2025, 2025, 2026 and 2027, respectively.
Ron Cohen, M.D., Acorda's President and CEO, said, “The court decision reflects the merits of the case we presented and the validity and strength of our intellectual property for AMPYRA.” The company stock showed a positive response to the verdict. It is now up over 60 percent this year so far, bringing its 12 months loss down to 16 percent.